Paragraph 9 Amendment of Schedule 6 (insertion of Schedule 12A into the 2012 Regulations)I1

re-number the existing paragraph as sub-paragraph (1) of paragraph 27; and

insert at the end—

“(2)

In this paragraph, “signal evaluation” means the process of further evaluating a validated signal taking into account all available evidence, to determine whether there are new risks causally associated with the active substance or medicinal product, or whether known risks have changed, and that process—

(a)

may include non-clinical and clinical data; and

(b)

must be as comprehensive as possible regarding the sources of information used for that process.”.